Real World Outcomes of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program with Commercial Lifileucel.

Key Points

• Therapeutic outcomes demonstrate significant improvement in melanoma cases treated with lifileucel.
• Data indicates a median overall survival of 21 months in patients undergoing this therapy.
• Observational analysis of patients treated at a single center provides valuable insights into the therapy's efficacy.
• Findings support the potential of lifileucel to enhance immune responses against melanoma.